Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled colistimethate sodium versus placebo for non-cystic fibrosis bronchiectasis with chronic Pseudomonas aeruginosa infection
MOH_2018-12-09_004832Phase 3Not yet recruiting
- Sponsor
- Zambon
- Start
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of colistimethate sodium in bronchiectasis and Pseudomonal infection (2 arms), sponsored by Zambon. Primary endpoint: Primary endpoint not reported. Planned start Dec 2018; status: not yet recruiting.
02
Drugs
colistimethate sodium
03
Conditions
bronchiectasisPseudomonal infection
Beyond the preview
Go deeper on MOH_2018-12-09_004832.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-12-09_004832.